Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then the New England Journal of Medicine, retracted studies that were based on inaccessible data. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. MORU researchers played a key role in bringing this scandal to light, whose consequences continue to play out.

Composite image of many hydroxychloroquine articles
Load More

Similar stories

Ensitrelvir shows strong antiviral activity against COVID-19 in first head-to-head comparison with Paxlovid

The oral antiviral ensitrelvir is a highly effective treatment for COVID-19, showing potent in-vivo antiviral activity comparable to ritonavir-boosted nirmatrelvir (Paxlovid), say MORU, Mahidol and University of Oxford researchers in a major international study published in The Lancet Infectious Diseases.